Browse News
Filter News
Found 806,105 articles
-
Citing a JAMA study that found Ozempic could be profitably produced at under $5 per month, Senator Bernie Sanders on Wednesday called on Novo Nordisk to lower prices for the diabetes treatment and the weight-loss drug Wegovy.
-
Keytruda can now be used in the European Union for patients with resectable non-small cell lung cancer at high risk of recurrence in combination with platinum chemotherapy, then continued as a monotherapy afterwards.
-
After an initial rejection due to safety issues, followed by a dispute and deferred actions, Akebia Therapeutics on Wednesday finally won the FDA’s nod for vadadustat as a treatment for anemia caused by chronic kidney disease.
-
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of...
3/28/2024
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United States. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, poli... -
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Stoke Therapeutics plans to offer up more than 5.5 million shares of its common stock following positive Phase I/IIa data for its Dravet syndrome candidate.
-
To avoid overextending yourself and harming your work-life balance, how should you set and maintain boundaries at work?
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Altimmune on Wednesday said it is ending development of HepTcell, a hepatitis B candidate, following disappointing trial results as it focuses on obesity and metabolic dysfunction-associated steatohepatitis.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
3/28/2024
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).
-
An ActRIIA Fusion Protein Got FDA Approved for PAH Treatment
3/28/2024
On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment.
-
Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033
3/28/2024
The global cell and gene therapy CDMO Market size was valued at USD 5.90 billion in 2023 and is projected to reach USD 69.11 billion by 2033,
-
Advanced Therapy Medicinal Products CDMO Industry is Rising Rapidly
3/28/2024
According to latest study, the global advanced therapy medicinal products CDMO Market size was valued at USD 6.10 billion in 2023 and is projected to reach USD 34.53 billion by 2033
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
Dermatology Devices Market Size, CAGR, Trends and Forecast 2024 to 2033
3/28/2024
According to Vision Research Reports, the global dermatology devices market size was estimated at USD 15.31 billion in 2023
-
Magritek makes benchtop NMR available for drug analysis in forensic labs
3/28/2024
The market-leading benchtop Nuclear Magnetic Resonance (NMR) developer, Magritek, introduces its qIDsolve benchtop NMR software package, which is quickly being adopted by forensics laboratories around the world.
-
Genetic Analysis Market Size to Attain Around USD 23.60 BN by 2033
3/28/2024
The global genetic analysis market was evaluated at USD 10.55 billion in 2023 and is expected to attain around USD 23.60 billion by 2033
-
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
3/28/2024
Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease.
-
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
3/28/2024
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months.